Filing Flows › Arrowhead Pharmaceuticals (ARWR) › Q2 FY25
Arrowhead Pharmaceuticals (ARWR) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed May 12, 2025
Arrowhead Pharmaceuticals (ARWR) reported revenue of $543M for the second quarter fiscal 2025 (Q2 FY25) and up 217-fold from the quarter before. Operating margin was 70.2%, net earnings $370M (68.3% of revenue).
Arrowhead Pharmaceuticals, Q2 FY25: revenue $543M, operating margin 70.2%, net earnings $370M, operating cash flow $460M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $543M | 217× | — |
| Operating profit | $381M | — | — |
| Net earnings | $370M | — | — |
| Operating cash flow | $460M | — | — |
| Free cash flow | $455M | — | — |
What changed
Revenue was $542.7M in Q2 FY25, up 21608% from the previous quarter.
Operating profit was $381.2M, a 70.2% margin. Net earnings were $370.4M ($367.9M including minority interests, which bore $2.6M of losses). The effective tax rate was 0.5%.
Operating cash flow was $460.1M, 125% of net earnings. Non-cash charges added back $5.6M of depreciation and amortization and $16.0M of share-based compensation. Working capital and other items added $70.6M. Capital expenditures of $5.3M left free cash flow of $454.8M.
Questions
What was Arrowhead Pharmaceuticals' revenue in the second quarter fiscal 2025?
Arrowhead Pharmaceuticals (ARWR) reported revenue of $543M for the second quarter fiscal 2025 (Q2 FY25) and up 217-fold from the quarter before.
Was Arrowhead Pharmaceuticals profitable in the second quarter fiscal 2025?
Operating profit was $381M (70.2% of revenue) and net earnings $370M.